A Genetic Interaction Analysis Identifies Cancer Drivers That Modify EGFR Dependency

Overview

Journal Genes Dev

Specialty Molecular Biology

Date 2017 Feb 8

PMID 28167502

Citations 43

Authors

Sida Liao

Teresa Davoli

Yumei Leng

Mamie Z Li

Qikai Xu

Stephen J Elledge

Affiliations

Soon will be listed here.

Abstract

A large number of cancer drivers have been identified through tumor sequencing efforts, but how they interact and the degree to which they can substitute for each other have not been systematically explored. To comprehensively investigate how cancer drivers genetically interact, we searched for modifiers of epidermal growth factor receptor (EGFR) dependency by performing CRISPR, shRNA, and expression screens in a non-small cell lung cancer (NSCLC) model. We elucidated a broad spectrum of tumor suppressor genes (TSGs) and oncogenes (OGs) that can genetically modify proliferation and survival of cancer cells when EGFR signaling is altered. These include genes already known to mediate EGFR inhibitor resistance as well as many TSGs not previously connected to EGFR and whose biological functions in tumorigenesis are not well understood. We show that mutation of , a subunit of the SWI/SNF complex, attenuates the effects of EGFR inhibition in part by sustaining AKT signaling. We also show that mutation of Capicua (), a transcriptional repressor, suppresses the effects of EGFR inhibition by partially restoring the EGFR-promoted gene expression program, including the sustained expression of Ets transcription factors such as Together, our data provide strong support for the hypothesis that many cancer drivers can substitute for each other in certain contexts and broaden our understanding of EGFR regulation.

Citing Articles

It's all downstream from here: RTK/Raf/MEK/ERK pathway resistance mechanisms in glioblastoma.

Yakubov R, Kaloti R, Persaud P, McCracken A, Zadeh G, Bunda S J Neurooncol. 2025; .

PMID: 39821893 DOI: 10.1007/s11060-024-04930-w.

State of the art CRISPR-based strategies for cancer diagnostics and treatment.

Di Carlo E, Sorrentino C Biomark Res. 2024; 12(1):156.

PMID: 39696697 PMC: 11657220. DOI: 10.1186/s40364-024-00701-x.

Research into overcoming drug resistance in lung cancer treatment using CRISPR-Cas9 technology: a narrative review.

Liu B, Wang Z, Gu M, Wang J, Tan J Transl Lung Cancer Res. 2024; 13(8):2067-2081.

PMID: 39263032 PMC: 11384501. DOI: 10.21037/tlcr-24-592.

Sotorasib with panitumumab in chemotherapy-refractory KRAS-mutated colorectal cancer: a phase 1b trial.

Kuboki Y, Fakih M, Strickler J, Yaeger R, Masuishi T, Kim E Nat Med. 2024; 30(1):265-270.

PMID: 38177853 PMC: 11135132. DOI: 10.1038/s41591-023-02717-6.

Multi-Omic Analysis of CIC's Functional Networks Reveals Novel Interaction Partners and a Potential Role in Mitotic Fidelity.

Takemon Y, Leblanc V, Song J, Chan S, Lee S, Trinh D Cancers (Basel). 2023; 15(10).

PMID: 37345142 PMC: 10216487. DOI: 10.3390/cancers15102805.

References

Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C . Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009; 361(10):958-67. DOI: 10.1056/NEJMoa0904554. View

Hollenhorst P, Ferris M, Hull M, Chae H, Kim S, Graves B . Oncogenic ETS proteins mimic activated RAS/MAPK signaling in prostate cells. Genes Dev. 2011; 25(20):2147-57. PMC: 3205585. DOI: 10.1101/gad.17546311. View

Stewart E, Tan S, Liu G, Tsao M . Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review. Transl Lung Cancer Res. 2015; 4(1):67-81. PMC: 4367712. DOI: 10.3978/j.issn.2218-6751.2014.11.06. View

Subramanian A, Tamayo P, Mootha V, Mukherjee S, Ebert B, Gillette M . Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102(43):15545-50. PMC: 1239896. DOI: 10.1073/pnas.0506580102. View

Cheng H, Fertig E, Ozawa H, Hatakeyama H, Howard J, Perez J . Decreased SMAD4 expression is associated with induction of epithelial-to-mesenchymal transition and cetuximab resistance in head and neck squamous cell carcinoma. Cancer Biol Ther. 2015; 16(8):1252-8. PMC: 4623002. DOI: 10.1080/15384047.2015.1056418. View

Shalem O, Sanjana N, Zhang F . High-throughput functional genomics using CRISPR-Cas9. Nat Rev Genet. 2015; 16(5):299-311. PMC: 4503232. DOI: 10.1038/nrg3899. View

Liao Y, Smyth G, Shi W . The Subread aligner: fast, accurate and scalable read mapping by seed-and-vote. Nucleic Acids Res. 2013; 41(10):e108. PMC: 3664803. DOI: 10.1093/nar/gkt214. View

Li W, Xu H, Xiao T, Cong L, Love M, Zhang F . MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens. Genome Biol. 2014; 15(12):554. PMC: 4290824. DOI: 10.1186/s13059-014-0554-4. View

Papadakis A, Sun C, Knijnenburg T, Xue Y, Grernrum W, Holzel M . SMARCE1 suppresses EGFR expression and controls responses to MET and ALK inhibitors in lung cancer. Cell Res. 2015; 25(4):445-58. PMC: 4387553. DOI: 10.1038/cr.2015.16. View

10.

Robinson M, McCarthy D, Smyth G . edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2009; 26(1):139-40. PMC: 2796818. DOI: 10.1093/bioinformatics/btp616. View

11.

Pirazzoli V, Nebhan C, Song X, Wurtz A, Walther Z, Cai G . Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1. Cell Rep. 2014; 7(4):999-1008. PMC: 4074596. DOI: 10.1016/j.celrep.2014.04.014. View

12.

Li M, Elledge S . SLIC: a method for sequence- and ligation-independent cloning. Methods Mol Biol. 2012; 852:51-9. DOI: 10.1007/978-1-61779-564-0_5. View

13.

Roch F, Jimenez G, Casanova J . EGFR signalling inhibits Capicua-dependent repression during specification of Drosophila wing veins. Development. 2002; 129(4):993-1002. DOI: 10.1242/dev.129.4.993. View

14.

Takezawa K, Pirazzoli V, Arcila M, Nebhan C, Song X, de Stanchina E . HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation. Cancer Discov. 2012; 2(10):922-33. PMC: 3473100. DOI: 10.1158/2159-8290.CD-12-0108. View

15.

Lee H, Dai F, Zhuang L, Xiao Z, Kim J, Zhang Y . BAF180 regulates cellular senescence and hematopoietic stem cell homeostasis through p21. Oncotarget. 2016; 7(15):19134-46. PMC: 4991371. DOI: 10.18632/oncotarget.8102. View

16.

Kuleshov M, Jones M, Rouillard A, Fernandez N, Duan Q, Wang Z . Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res. 2016; 44(W1):W90-7. PMC: 4987924. DOI: 10.1093/nar/gkw377. View

17.

Costa C, Ebi H, Martini M, Beausoleil S, Faber A, Jakubik C . Measurement of PIP3 levels reveals an unexpected role for p110β in early adaptive responses to p110α-specific inhibitors in luminal breast cancer. Cancer Cell. 2014; 27(1):97-108. PMC: 4745884. DOI: 10.1016/j.ccell.2014.11.007. View

18.

Yamamoto C, Basaki Y, Kawahara A, Nakashima K, Kage M, Izumi H . Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinib-resistant lung cancer cells harboring epidermal growth factor receptor-activating mutations. Cancer Res. 2010; 70(21):8715-25. DOI: 10.1158/0008-5472.CAN-10-0043. View

19.

Takekawa M, Tatebayashi K, Itoh F, Adachi M, Imai K, Saito H . Smad-dependent GADD45beta expression mediates delayed activation of p38 MAP kinase by TGF-beta. EMBO J. 2002; 21(23):6473-82. PMC: 136947. DOI: 10.1093/emboj/cdf643. View

20.

Majem M, Remon J . Tumor heterogeneity: evolution through space and time in EGFR mutant non small cell lung cancer patients. Transl Lung Cancer Res. 2015; 2(3):226-37. PMC: 4367601. DOI: 10.3978/j.issn.2218-6751.2013.03.09. View